Document is current
Any future updates will be listed below
-
Authors
Shallis, Rory M. https://orcid.org/0000-0002-8542-2944
Pucar, Darko
Perincheri, Sudhir
Gore, Steven D.
Seropian, Stuart E.
Podoltsev, Nikolai A.
Zeidan, Amer M.
- License Information
-
More Information
Article History
Received: 17 July 2021
Accepted: 14 October 2021
First Online: 22 October 2021
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Informed consent was obtained from the individual described in this publication.
: A.M.Z. received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics. A.M.Z participated in advisory boards, and/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, and Tyme. A.M.Z received travel support for meetings from Pfizer, Novartis, and Trovagene. N.A.P. consulted for and received honoraria from Alexion, Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene, Bristol-Myers Squib, CTI BioPharma, PharmaEssentia, and Constellation Pharmaceuticals. N.A.P. received research funding (all to the institution) from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTI biopharma, Celgene, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals, and Kartos Therapeutics. None of these relationships was related to the development of this manuscript. All other authors report no relevant disclosures/competing interests.
